Skip to main content

Nicotinamide as an Early Alzheimer's Treatment (NEAT)

Recruiting

Nicotinamide, or niacinamide, is a form of vitamin B3 that researchers are exploring for its possible use in reducing tau, a protein that accumulates in tangles in the brain's of people with Alzheimer's disease. This study will test the effects of a high dose of nicotinamide in adults with mild cognitive impairment (MCI) or mild Alzheimer's disease.

Minimum Age Maximum Age Gender Healthy Volunteers
50 Years N/A All No
July 12, 2017
June 30, 2020
48

  • MCI or Alzheimer's disease
  • Meets biomarker criteria as outlined by the study
  • Mini-Mental State Examination score of 20 or higher
  • Blood laboratories, urinalysis, and electrocardiogram within normal limits or deemed clinically not significant
  • Stable medications (including approved Alzheimer's drugs) for at least 4 weeks
  • At least 6 years of education
  • Able to swallow oral tablets
  • Fluent in English
  • Study partner with in-person contact three or more times per week

  • Neurological or psychiatric diagnosis other than Alzheimer's that may affect cognition and/or function
  • Inability to undergo lumbar puncture, including use of warfarin (Coumadin, Jantoven), novel oral anticoagulants, clopidogrel (Plavix), or dipyridamole (Permole, Persantine). Use of 325mg or less of aspirin daily is permitted.
  • Inability to undergo magnetic resonance imaging (MRI)
  • MRI evidence of cortical stroke greater than 1 cm, or certain deposits or lesions
  • Hachinski Ischemic Score of 4 or higher
  • Diagnosis of cancer in past 5 years (except basal or squamous cell carcinoma)
  • Geriatric Depression Scale score of 6 or higher
  • Alcohol or substance use disorder in past 5 years
  • Active malabsorptive disorder, such as celiac disease
  • Residence in a skilled nursing facility
  • Participation in a clinical trial of a potential Alzheimer's disease-modifying therapy in past 6 months
  • Pregnant, lactating, or of childbearing potential
  • Unwillingness to abstain from over-the-counter nicotinamide

In this Phase II trial, participants will be randomized to take 2 tablets daily of either nicotinamide or a placebo pill for 48 weeks. Researchers will measure changes in tau levels in cerebrospinal fluid. The study includes 4 study visits. An additional 12-month treatment and follow-up period is possible, contingent on initial findings.

Name City State Zip Status Primary Contact
University of California, Irvine
Irvine California 92697 Recruiting Beatriz Yanez, R.N
949-824-0008
byanez@uci.edu
University of California, Los Angeles
Los Angeles California 90095 Recruiting Celine Ossinalde, MA
310-794-6191
cossinalde@mednet.ucla.edu

University of California, Irvine

Name Role Affiliation
Joshua Grill, PhD Principal Investigator Associate Professor of Psychiatry and Human Behavior

Name Phone Email
Joshua Grill, PhD 949-824-5905 jgrill@uci.edu
Megan Witbracht, PhD 949-824-3249 mwitbrac@uci.edu

NCT03061474

A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia